JP2018536170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536170A5 JP2018536170A5 JP2018532841A JP2018532841A JP2018536170A5 JP 2018536170 A5 JP2018536170 A5 JP 2018536170A5 JP 2018532841 A JP2018532841 A JP 2018532841A JP 2018532841 A JP2018532841 A JP 2018532841A JP 2018536170 A5 JP2018536170 A5 JP 2018536170A5
- Authority
- JP
- Japan
- Prior art keywords
- plgf
- sflt
- plap
- blood glucose
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100035194 Placenta growth factor Human genes 0.000 claims 40
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 33
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims 24
- 108010031345 placental alkaline phosphatase Proteins 0.000 claims 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 20
- 239000008103 glucose Substances 0.000 claims 20
- 239000008280 blood Substances 0.000 claims 18
- 210000004369 blood Anatomy 0.000 claims 18
- 208000004104 gestational diabetes Diseases 0.000 claims 9
- 210000003731 gingival crevicular fluid Anatomy 0.000 claims 9
- 230000014509 gene expression Effects 0.000 claims 8
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims 7
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims 3
- 230000002018 overexpression Effects 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108010074415 Angiogenic Proteins Proteins 0.000 claims 1
- 102000008076 Angiogenic Proteins Human genes 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 238000007410 oral glucose tolerance test Methods 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217270P | 2015-09-11 | 2015-09-11 | |
| US62/217,270 | 2015-09-11 | ||
| EP16161490.4 | 2016-03-21 | ||
| EP16161490 | 2016-03-21 | ||
| PCT/IB2016/055426 WO2017042751A1 (en) | 2015-09-11 | 2016-09-12 | In vitro method for identifying a pregnancy related disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536170A JP2018536170A (ja) | 2018-12-06 |
| JP2018536170A5 true JP2018536170A5 (enExample) | 2019-10-24 |
Family
ID=55646323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532841A Pending JP2018536170A (ja) | 2015-09-11 | 2016-09-12 | 妊娠関連疾患を同定するｉｎ ｖｉｔｒｏ方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11009512B2 (enExample) |
| EP (2) | EP3502705B1 (enExample) |
| JP (1) | JP2018536170A (enExample) |
| CN (1) | CN108700591A (enExample) |
| AU (1) | AU2016319010A1 (enExample) |
| CA (1) | CA2998275A1 (enExample) |
| WO (1) | WO2017042751A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002788A (es) | 2017-09-13 | 2020-09-14 | Progenity Inc | Biomarcadores de preeclampsia y sistemas y metodos relacionados. |
| CN113692624A (zh) * | 2019-02-14 | 2021-11-23 | 米尔维公司 | 用于确定受试者的妊娠相关状态的方法和系统 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113308533B (zh) * | 2021-05-31 | 2023-10-24 | 东莞市人民医院 | 妊娠期糖尿病患者胎盘来源外泌体miRNA表达分析方法 |
| GB202219102D0 (en) * | 2022-12-16 | 2023-02-01 | Univ Oxford Innovation Ltd | Method |
| CN117647653B (zh) * | 2023-12-22 | 2024-05-07 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 一种与子痫前期相关的生物标志物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005017192A2 (en) * | 2003-08-14 | 2005-02-24 | The General Hospital Corporation | Screening for gestational disorders |
| ATE519109T1 (de) | 2004-12-21 | 2011-08-15 | Univ Yale | Präeklampsie-diagnose |
| CA2625744A1 (en) * | 2005-10-11 | 2007-04-19 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| JP2010502946A (ja) * | 2006-09-01 | 2010-01-28 | アメリカン タイプ カルチャー コレクション | ２型糖尿病を診断および処置するための組成物および方法 |
| US20080300170A1 (en) * | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| EP2494483A2 (en) * | 2009-10-29 | 2012-09-05 | Tethys Bioscience, Inc. | Method for determining risk of diabetes |
| SG11201506891YA (en) * | 2013-03-12 | 2015-09-29 | Agency Science Tech & Res | Pre-eclampsia biomarkers |
-
2016
- 2016-09-12 CA CA2998275A patent/CA2998275A1/en not_active Abandoned
- 2016-09-12 US US15/758,706 patent/US11009512B2/en active Active
- 2016-09-12 CN CN201680066289.4A patent/CN108700591A/zh active Pending
- 2016-09-12 JP JP2018532841A patent/JP2018536170A/ja active Pending
- 2016-09-12 EP EP19153119.3A patent/EP3502705B1/en active Active
- 2016-09-12 AU AU2016319010A patent/AU2016319010A1/en not_active Abandoned
- 2016-09-12 EP EP16766645.2A patent/EP3347719B1/en active Active
- 2016-09-12 WO PCT/IB2016/055426 patent/WO2017042751A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536170A5 (enExample) | ||
| Celikbilek et al. | Neutrophil to lymphocyte ratio predicts poor prognosis in ischemic cerebrovascular disease | |
| Aitken et al. | α‐2‐macroglobulin in saliva is associated with glycemic control in patients with type 2 diabetes mellitus | |
| JP2009501333A5 (enExample) | ||
| Inoue et al. | Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies | |
| AR060120A1 (es) | Medio y metodo para diagnosticar la diabetes | |
| JP2017504011A5 (enExample) | ||
| JP6415546B2 (ja) | 脳卒中の鑑別診断を支援する方法 | |
| JP2013504766A5 (enExample) | ||
| RU2019143570A (ru) | Диагностика периодонтита на основании hgf и mmp-8 в слюне | |
| WO2010150254A3 (en) | A method and system for the detection of cancer | |
| CN105021827B (zh) | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 | |
| JP2014505254A5 (enExample) | ||
| Shigefuku et al. | Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease | |
| CN103293250A (zh) | 糖尿病肾病诊断试剂盒及其应用 | |
| JP2019510974A5 (enExample) | ||
| Canney et al. | Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease | |
| RU2008103988A (ru) | Способ диагностики рассеяного склероза | |
| Apica et al. | Decompensated cirrhosis-related admissions in a large urban hospital in Uganda: prevalence, clinical and laboratory features and implications for planning patient management | |
| Merchante et al. | Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis | |
| JP2021510815A5 (enExample) | ||
| RU2020127365A (ru) | Способы, применения и комплекты для диагностики пародонтита | |
| Kus et al. | Optic nerve sheath diameters predict mortality and severity in hepatic encephalopathy | |
| CN107091934B (zh) | 一种直接胆红素测定试剂盒及配置方法以及其运用 | |
| JP2015528562A5 (enExample) |